Securities code: Zhejiang Gongdong Medical Technology Co.Ltd(605369) securities abbreviation: Zhejiang Gongdong Medical Technology Co.Ltd(605369) Announcement No.: 2022009
Zhejiang Gongdong Medical Technology Co.Ltd(605369)
Announcement on the change of the company’s chief financial officer
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Zhejiang Gongdong Medical Technology Co.Ltd(605369) (hereinafter referred to as “the company”) the board of directors recently received a written resignation report from Ms. Jiang Xixi, the chief financial officer of the company. Due to job adjustment, Ms. Jiang Xixi applied to resign as the chief financial officer of the company. After resigning as the chief financial officer, she will continue to hold other positions in the company.
In accordance with the company law, the articles of association and other relevant provisions, Ms. Jiang Xixi’s resignation report shall take effect from the date when it is delivered to the board of directors of the company. Ms. Jiang Xixi’s resignation will not affect the company’s production and operation. As of the disclosure date of this announcement, Ms. Jiang Xixi has directly held 12000 shares of the company (granted by the company’s 2021 restricted stock incentive plan). After her resignation as chief financial officer, she will continue to hold the restricted shares in accordance with the relevant provisions of the company’s 2021 restricted stock incentive plan (Draft).
Upon the nomination of the general manager and the review of the nomination committee of the board of directors, the proposal on the appointment of the company’s chief financial officer was deliberated and adopted at the 15th meeting of the second board of directors on April 15, 2022, and it was agreed to appoint Mr. Pan Lei as the company’s chief financial officer. The term of office starts from the date of deliberation and approval of the board of directors to the date of expiration of the term of office of the second board of directors. Independent directors have expressed their independent opinions on the matter.
As of the disclosure date of this announcement, Mr. Pan Lei did not directly hold the shares of the company and indirectly held 0.224% of the shares of the company through Taizhou Jinchi investment management partnership (limited partnership). It has no relationship with the company’s controlling shareholders, actual controllers, other directors, supervisors, senior managers and shareholders holding more than 5% of the company’s shares. It is not allowed to serve as the company’s senior managers as stipulated in the company law and the articles of association, nor has it been punished by the CSRC and other relevant penalties and stock exchanges. It is hereby announced.
Zhejiang Gongdong Medical Technology Co.Ltd(605369) board of directors April 18, 2022
Attachment: resume of Mr. Pan Lei
Mr. Pan Lei, born in February 1984, Chinese nationality, without overseas permanent residency, master’s degree, certified public accountant, senior accountant and Chinese certified tax agent. From March 2009 to October 2017, he served as the audit manager of Tianjian Certified Public Accountants (special general partnership); From October 2017 to April 2021, served as Zhejiang Gongdong Medical Technology Co.Ltd(605369) chief financial officer; From December 2021 to now, he has served as Hainan Poly Pharm.Co.Ltd(300630) independent director; In April 2022, he joined Zhejiang Gongdong Medical Technology Co.Ltd(605369) .
